Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: A randomized phase i proof-of-principle clinical study in women of reproductive age

Reproductive Sciences

Volumn 21, Issue 10, 2014, Pages 1256-1265

  Pohl, Oliver ^a   Bestel, Elke ^a   Gotteland, Jean Pierre ^a  

^a Product and Clinical Development   (Switzerland)

Author keywords

E2MATE; endometriosis; norethindrone acetate; phase I clinical trial; steroid sulfatase inhibition

Indexed keywords

ESTROGEN; NORETHISTERONE ACETATE; PGL 2001; PLACEBO; UNCLASSIFIED DRUG; ESTRADIOL; ESTRADIOL-3-O-SULFAMATE; NORETHISTERONE; STERYL SULFATASE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ENDOMETRIUM; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN TISSUE; MENSTRUAL IRREGULARITY; METRORRHAGIA; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTION; RHINOPHARYNGITIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; NORETHINDRONE; REPRODUCTION; STERYL-SULFATASE; YOUNG ADULT;

EID: 84908884897     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114522526     Document Type: Article

References (36)

1. Rogers PA, D'Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009; 16 (4). 335-346
2. Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril. 2010; 94 (5). 1609-1615
3. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011; 18 (9). 814-823
4. Streuli I, de ZD, Borghese B, Santulli P, Batteux F, Chapron C. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2012; 17 (1). 83-104
5. Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012; 21 (7). 905-919
6. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002; 83 (1-5). 149-155
7. Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol. 2012; 212 (2). 99-110
8. Purohit A, Woo LW, Potter BV. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol. 2011; 340 (2). 154-160
9. Woo LW, Purohit A, Potter BV. Development of steroid sulfatase inhibitors. Mol Cell Endocrinol. 2011; 340 (2). 175-185
10. Maltais R, Poirier D. Steroid sulfatase inhibitors: a review covering the promising 2000-2010 decade. Steroids. 2011; 76 (10-11). 929-948
11. Zeitoun K, Takayama K, Sasano H, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab. 1998; 83 (12). 4474-4480
12. Smuc T, Pucelj MR, Sinkovec J, Husen B, Thole H, Lanisnik RT. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecol Endocrinol. 2007; 23 (2). 105-111
13. Smuc T, Hevir N, Ribic-Pucelj M, Husen B, Thole H, Rizner TL. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol. 2009; 301 (1-2). 59-64
14. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab. 2009; 94 (3). 876-883
15. Bulun SE, Imir G, Utsunomiya H, et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005; 95 (1-5). 57-62
16. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 2004; 1654 (2). 123-143
17. Carlstrom K, Bergqvist A, Ljungberg O. Metabolism of estrone sulfate in endometriotic tissue and in uterine endometrium in proliferative and secretory cycle phase. Fertil Steril. 1988; 49 (2). 229-233
18. Yamamoto T, Noguchi T, Tamura T, Kitawaki J, Okada H. Evidence for estrogen synthesis in adenomyotic tissues. Am J Obstet Gynecol. 1993; 169 (3). 734-738
19. Ezaki K, Motoyama H, Sasaki H. Immunohistologic localization of estrone sulfatase in uterine endometrium and adenomyosis. Obstet Gynecol. 2001; 98 (5 pt 1). 815-819
20. Utsunomiya H, Ito K, Suzuki T, et al. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res. 2004; 10 (17). 5850-5856
21. Dassen H, Punyadeera C, Kamps R, et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod. 2007; 22 (12). 3148-3158
22. Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod. 2008; 23 (2). 290-297
23. Howarth NM, Purohit A, Reed MJ, Potter BV. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem. 1994; 37 (2). 219-221
24. Elger W, Palme HJ, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Expert Opin Investig Drugs. 1998; 7 (4). 575-589
25. Sahlin L, Elger W, Hedden A, et al. Effects of estradiol and estradiol sulfamate on the liver of ovariectomized or ovariectomized and hypophysectomized rats. J Steroid Biochem Mol Biol. 2002; 80 (4-5). 457-467
26. Ho YT, Purohit A, Vicker N, et al. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun. 2003; 305 (4). 909-914
27. MacCarthy-Morrogh L, Townsend PA, Purohit A, et al. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res. 2000; 60 (19). 5441-5450
28. Chander SK, Purohit A, Woo LW, Potter BV, Reed MJ. The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem Biophys Res Commun. 2004; 322 (1). 217-222
29. Colette S, Defrere S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod. 2011; 26 (6). 1362-1370
30. Vercellini P, Pietropaolo G, De GO, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005; 84 (5). 1375-1387
31. Vercellini P, Somigliana E, Vigano P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol. 2008; 22 (2). 275-306
32. Loebl EC, Baxter CR, Curreri PW. The mechanism of erythrocyte destruction in the early post-burn period. Ann Surg. 1973; 178 (6). 681-686
33. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003; 86 (3-5). 225-230
34. Maitoko K, Sasaki H. Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary. Fertil Steril. 2004; 82 (2). 322-326
35. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J. 1997; 11 (4). 206-216
36. Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998; 43 (1). 24-27